As filed with the U.S. Securities and Exchange Commission on January 28, 2026 Registration No. 333-292789 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INSPIRE VETERINARY PARTNERS, INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 8900 85-4359258 (State or jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identif ...

As filed with the U.S. Securities and Exchange Commission on January 16, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INSPIRE VETERINARY PARTNERS, INC. (Exact Name of Registrant as Specified in Its Charter) | Nevada | 8900 | 85-4359258 | | --- | --- | --- | | (State or jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organization) | Classification Code ...

Core Insights - Vivos Inc.'s IsoPet division experienced a remarkable 1,200% year-over-year increase in administered therapies from 2024 to 2025, indicating a significant rise in veterinary adoption and demand for IsoPet therapy [1] - The company is implementing profitability-focused initiatives starting in Q1 2026 while expanding its network of certified clinics [1] Expansion of Services - Over 100 IsoPet treatments have been successfully performed on various animals, including dogs, cats, horses, and exotic animals [2] - Sun City Veterinary Surgery Center in El Paso, Texas, has become the first companion animal hospital in Texas certified to offer IsoPet therapy, enhancing access to advanced cancer treatment for pets in the region [3][4] - The University of Florida Small Animal Hospital has also been certified to provide IsoPet therapy, making it one of the few academic veterinary centers to offer this service for both small and large animals [5][6] Clinical Outcomes and Research - Seventeen patients were treated in November and thirteen in December, marking an all-time high for the IsoPet division [7] - The completion of case study therapies is expected to lead to multiple publications in 2026, which will aid in marketing efforts to veterinarians and oncologists [7] - A strategic partnership with Exubrion Therapeutics aims to co-market IsoPet in the equine oncology segment, which is identified as a high-growth opportunity [8]

Kennewick, WA, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) The IsoPet division reported an 800% year-over-year increase in administered therapies from 2024 to 2025, reflecting accelerating veterinary adoption nationwide. In recent months, the Company has seen a sharp rise in inbound inquiries from both veterinarians and pet owners seeking access to IsoPet therapy, signaling growing awareness and demand for this precise, cost-effective alternative to traditional radiation. Starting in Q1 2026, ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. Ringpai Veterinary Hospital Management Holdings Co., Ltd. （瑞派寵物醫院管理股份有限公司） (the "Company") (A joint stock company incorporated in the People's Rep ...

As filed with the U.S. Securities and Exchange Commission on December 5, 2025 Registration No. 333-290722 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INSPIRE VETERINARY PARTNERS, INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 8900 85-4359258 (State or jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identif ...

Core Viewpoint - Zacks Investment Research has initiated coverage of Inspire Veterinary Partners Inc. (IVP) with an Underperform rating due to ongoing financial challenges and structural issues that may hinder shareholder returns in the near to medium term [1] Financial Performance - Inspire Veterinary reported year-to-date net losses of $8 million and an accumulated deficit of $44.3 million as of Q3 2025, raising concerns about its viability as a going concern [2] - The company has negative working capital of $5.9 million and relies on high-cost external financing, with some interest rates exceeding 50% [3] - Revenue declined to $12.2 million in the first nine months of 2025 from $13.3 million in the same period in 2024, indicating that its acquisition-led growth model is not yet yielding consistent revenue growth [4] - The company recorded a negative operating cash flow of $3.6 million in the first nine months of 2025, continuing a trend of cash burn that necessitates ongoing external funding [5] Growth Strategy - Inspire Veterinary aims to expand to 50 hospitals by 2029 and reach $40 million in annual revenues by 2027, with plans to launch an online pet pharmacy in early 2026 to create a new high-margin revenue stream [6] - The company secured up to $10 million in new financing through a convertible preferred offering in August 2025, which enhances near-term liquidity and supports acquisitions [7] - Management targets cash flow breakeven by mid-2026, focusing on improved clinic-level efficiencies and cost control initiatives [7] Market Sentiment - Shares of Inspire Veterinary have significantly declined this year, reflecting investor concerns regarding the company's financial trajectory and strategic execution [8] - The stock trades at levels indicating low market confidence in the company's ability to achieve sustainable growth or profitability in the near term [8] Industry Context - Despite operating in a growing U.S. veterinary services market, Inspire Veterinary faces substantial financial and operational challenges, including reliance on external funding, ongoing losses, and shareholder dilution [9]

Core Insights - A significant portion of U.S. pet owners, 52%, have skipped necessary veterinary care in the past year due to costs, with an additional 15% avoiding vet visits for financial reasons [1][2] - The rising costs of veterinary care have led to an increase in pet insurance coverage, with over 6.4 million pets insured in 2024, marking a nearly 13% increase from 2023 [3] - Veterinary care costs in the U.S. have surged more than 60% since 2014, contributing to the financial strain on pet owners [6] Pet Insurance Market - The average annual premium for accident and illness pet insurance in 2024 is approximately $749 for dogs and $386 for cats, while accident-only policies cost around $193 for dogs and $110 for cats [10] - Pet insurance policies generally fall into three categories: accident-only, accident and illness, and wellness plans, with the latter covering routine expenses [8] - Most insurance policies cover emergency surgeries and treatments for diseases but typically exclude pre-existing conditions [9] Veterinary Costs - Routine checkup costs range from $70 to $174 for dogs and $53 to $124 for cats, while hospitalization can cost between $600 to $3,500 depending on the duration [7] - Emergency surgeries can range from $1,500 to $5,000, highlighting the financial burden pet owners may face [7] Financial Considerations - Pet owners must consider deductibles, reimbursement percentages, and annual limits when selecting insurance policies, with deductibles typically ranging from 10% to 30% [11] - It is essential for pet owners to have sufficient funds to cover vet bills upfront, as reimbursement from insurers can take up to 30 days [16] - Alternatives to pet insurance include self-funding pet healthcare through savings accounts, which can be more financially beneficial if the pet remains healthy [17]

Core Insights - Several companies have emerged as significant losers in the market, experiencing notable price drops and volatility [1][7] Company Summaries - **OneConstruction Group Limited (ONEG)**: The company's stock price fell to $2.35, a decrease of 54.18%. Revenue decreased by 16.2% to $53.2 million for the fiscal year ending March 31, 2025, raising concerns about market sentiment and operational challenges [2][8] - **SCHMID Group N.V. Warrants (SHMDW)**: The stock price decreased by 53.97% to $0.41. The decline from a year-high of $0.9651 to a low of $0.36 may reflect market reactions to company performance or broader industry trends [3][8] - **Taitron Components Incorporated (TAIT)**: The stock price dropped to $1.12, a 46.56% decrease. Despite this, the company declared a quarterly cash dividend of $0.035 per share, aiming for an annual dividend of $0.14 per share. The decline from a high of $5.1 to a low of $1.11 may be influenced by operational challenges or shifts in demand within the technology sector [4][8] - **Inspire Veterinary Partners, Inc. (IVP)**: The company's stock price decreased by 39.99% to $0.46. However, it reported a 7% increase in total revenues to $4.3 million and a 27% reduction in net losses for the third quarter of 2025. The downturn from a high of $6.3 to a low of $0.419 could be attributed to market sentiment or competitive pressures [5][8] - **Republic Power Group Limited Class A Ordinary Shares (RPGL)**: The stock price fell to $0.51, a 38.97% drop. The company closed its initial public offering on October 15, 2025, with shares priced at $4.00 each. The decline from a year-high of $5.19 to a low of $0.4551 suggests challenges that may include market competition or operational hurdles [6][8]

More pricing transparency in the UK veterinary industry is welcome, but don't expect lower pet-care bills, writes @chrismbryant (via @opinion) https://t.co/O8Nai4YgCo ...